Search Page

1

Cite

Share

Cisplatin nephrotoxicity: mechanisms and renoprotective strategies.

Pabla N, Dong Z. Pabla N, et al. Kidney Int. 2008 May;73(9):994-1007. doi: 10.1038/sj.ki.5002786. Epub 2008 Feb 13. Kidney Int. 2008. PMID: 18272962 Free article. Review.

Cite

Share

2

Cite

Share

DNA damage response in cisplatin-induced nephrotoxicity.

Zhu S, Pabla N, Tang C, He L, Dong Z. Zhu S, et al. Among authors: pabla n. Arch Toxicol. 2015 Dec;89(12):2197-205. doi: 10.1007/s00204-015-1633-3. Epub 2015 Nov 13. Arch Toxicol. 2015. PMID: 26564230 Free PMC article. Review.

Cite

Share

3

Cite

Share

Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice.

Huang KM, Leblanc AF, Uddin ME, Kim JY, Chen M, Eisenmann ED, Gibson AA, Li Y, Hong KW, DiGiacomo D, Xia SH, Alberti P, Chiorazzi A, Housley SN, Cope TC, Sprowl JA, Wang J, Loprinzi CL, Noonan A, Lustberg MB, Cavaletti G, Pabla N, Hu S, Sparreboom A. Huang KM, et al. Among authors: pabla n. J Clin Invest. 2020 Sep 1;130(9):4601-4606. doi: 10.1172/JCI136796. J Clin Invest. 2020. PMID: 32484793 Free PMC article.

Cite

Share

4

Cite

Share

Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia.

Zavorka Thomas ME, Jeon JY, Talebi Z, Buelow DR, Silvaroli J, Campbell MJ, Sparreboom A, Pabla N, Baker SD. Zavorka Thomas ME, et al. Among authors: pabla n. Blood Adv. 2021 Dec 14;5(23):5041-5046. doi: 10.1182/bloodadvances.2021005614. Blood Adv. 2021. PMID: 34614509 Free article.

Cite

Share

5

Cite

Share

Ribociclib mitigates cisplatin-associated kidney injury through retinoblastoma-1 dependent mechanisms.

Kim JY, Jayne LA, Bai Y, Feng MJHH, Clark MA, Chung S, W Christman J, Cianciolo RE, Pabla NS. Kim JY, et al. Among authors: pabla ns. Biochem Pharmacol. 2020 Jul;177:113939. doi: 10.1016/j.bcp.2020.113939. Epub 2020 Mar 27. Biochem Pharmacol. 2020. PMID: 32229099 Free PMC article.

Cite

Share

6

Cite

Share

Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.

Bai Y, Kim JY, Bisunke B, Jayne LA, Silvaroli JA, Balzer MS, Gandhi M, Huang KM, Sander V, Prosek J, Cianciolo RE, Baker SD, Sparreboom A, Jhaveri KD, Susztak K, Bajwa A, Pabla NS. Bai Y, et al. Among authors: pabla ns. Kidney Int. 2021 Dec;100(6):1214-1226. doi: 10.1016/j.kint.2021.08.022. Epub 2021 Sep 15. Kidney Int. 2021. PMID: 34534550

Cite

Share

7

Cite

Share

Checkpoint kinase 1 in DNA damage response and cell cycle regulation.

Patil M, Pabla N, Dong Z. Patil M, et al. Among authors: pabla n. Cell Mol Life Sci. 2013 Nov;70(21):4009-21. doi: 10.1007/s00018-013-1307-3. Epub 2013 Mar 19. Cell Mol Life Sci. 2013. PMID: 23508805 Free PMC article. Review.

Cite

Share

8

Cite

Share

Role of Passive Diffusion, Transporters, and Membrane Trafficking-Mediated Processes in Cellular Drug Transport.

Cocucci E, Kim JY, Bai Y, Pabla N. Cocucci E, et al. Among authors: pabla n. Clin Pharmacol Ther. 2017 Jan;101(1):121-129. doi: 10.1002/cpt.545. Epub 2016 Nov 26. Clin Pharmacol Ther. 2017. PMID: 27804130 Review.

Cite

Share

9

Cite

Share

Curtailing side effects in chemotherapy: a tale of PKCδ in cisplatin treatment.

Pabla N, Dong Z. Pabla N, et al. Oncotarget. 2012 Jan;3(1):107-11. doi: 10.18632/oncotarget.439. Epub 2012 Jan 31. Oncotarget. 2012. PMID: 22403741 Free PMC article. Review.

Cite

Share

10

Cite

Share

Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity.

Hu S, Leblanc AF, Gibson AA, Hong KW, Kim JY, Janke LJ, Li L, Vasilyeva A, Finkelstein DB, Sprowl JA, Sweet DH, Schlatter E, Ciarimboli G, Schellens J, Baker SD, Pabla N, Sparreboom A. Hu S, et al. Among authors: pabla n. Clin Transl Sci. 2017 Sep;10(5):412-420. doi: 10.1111/cts.12480. Epub 2017 Jul 8. Clin Transl Sci. 2017. PMID: 28689374 Free PMC article.

Cite

Share